Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines

Vector-based SARS-CoV-2 vaccines have been associated with vaccine- induced thrombosis with thrombocytopenia syndrome (VITT/TTS), but the causative factors are still unresolved. We comprehensively analyzed the ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Johnson & Johnson) vaccines. ChAdOx1 nC...

Descripción completa

Detalles Bibliográficos
Autores principales: Michalik, Stephan, Siegerist, Florian, Palankar, Raghavendra, Franzke, Kati, Schindler, Maximilian, Reder, Alexander, Seifert, Ulrike, Cammann, Clemens, Wesche, Jan, Steil, Leif, Hentschker, Christian, Gesell-Salazar, Manuela, Reisinger, Emil, Beer, Martin, Endlich, Nicole, Greinacher, Andreas, Völker, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968905/
https://www.ncbi.nlm.nih.gov/pubmed/35045692
http://dx.doi.org/10.3324/haematol.2021.280154
Descripción
Sumario:Vector-based SARS-CoV-2 vaccines have been associated with vaccine- induced thrombosis with thrombocytopenia syndrome (VITT/TTS), but the causative factors are still unresolved. We comprehensively analyzed the ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Johnson & Johnson) vaccines. ChAdOx1 nCoV-19 contains significant amounts of host cell protein impurities, including functionally active proteasomes, and adenoviral proteins. A much smaller amount of impurities was found in Ad26.COV2.S. Platelet factor 4 formed complexes with ChAdOx1 nCoV-19 constituents, but not with purified virions from ChAdOx1 nCoV-19 or with Ad26.COV2.S. Vascular hyperpermeability was induced by ChAdOx nCoV-19 but not by Ad26.COV2.S. These differences in impurities together with EDTAinduced capillary leakage might contribute to the higher incidence rate of VITT associated with ChAdOx1 nCoV-19 compared to Ad26.COV2.S.

Ejemplares similares